Comparative Pharmacology
Head-to-head clinical analysis: MYCHEL versus TRIMPEX 200.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MYCHEL versus TRIMPEX 200.
MYCHEL vs TRIMPEX 200
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mychel is a topical antifungal agent that inhibits ergosterol synthesis by binding to fungal cytochrome P450 14α-demethylase, disrupting fungal cell membrane integrity.
Trimethoprim inhibits bacterial dihydrofolate reductase, blocking the conversion of dihydrofolic acid to tetrahydrofolic acid, thereby inhibiting bacterial DNA synthesis.
Adults: 200 mg orally twice daily for 14 days.
200 mg orally once daily, or 100 mg orally twice daily.
None Documented
None Documented
Terminal half-life: 8.5-12 hours (mean 10.2 h) in normal renal function; prolonged to 18-30 h in severe renal impairment (CrCl <30 mL/min)
Terminal elimination half-life is 8-10 hours in adults with normal renal function; prolonged to 20-30 hours in renal impairment (CrCl <30 mL/min), requiring dose adjustment.
Renal: ~70% unchanged; fecal: ~15% as metabolites; biliary: ~10%
Renal excretion of unchanged drug accounts for approximately 60-80% of elimination, with an additional 10-20% as hepatic metabolites excreted in bile and feces.
Category C
Category C
Antibiotic
Antibiotic